Company claims the agency approved the generic although the innovator drug had not been fully characterized, but odds are against a Sanofi win in court. read more
Advisory committee will be asked to support the use of a hemodynamic endpoint in pediatric trials of Pfizer's Revatio (sildenafil). read more
Specifics of the accusations against the French pharma aren't clear, but it could face a fine amounting to 1 percent of annual sales. read more
Sandoz has a monopoly on the generic enoxaparin market for now, but Teva insists its ANDA is progressing at FDA. read more
Medco is launching a preliminary study to find out whether doubling the usual dose of Bristol-Myers Squibb's Plavix can offset the problem of reduced effectiveness that comes with concurrent use of a proton pump inhibitor and show that Plavix can still be as effective in certain patients as its newer and more expensive competitor, Effient. read more
The current system in which medicines are packaged according to a given number of units per pack would be replaced by a three-tier system in which drugs were packaged according to the length of the treatment required. read more
Glenmark likely to drop DPP-4 and vanilloid compounds returned by pharma licensors and focus on new outlicensing opportunities, including biologics. read more
"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here
